IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen

CAR-T Digest - August 2020

Monthly Digest - August 2024

31 July 2024: IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen

IDEAYA Biosciences and Biocytogen Pharmaceuticals have entered into an option and license agreement for a potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) program
B7H3/PTK7 is co-expressed in various solid tumors, including lung, colorectal, and head and neck cancers, with notable prevalence in these types
The program is expected to be a potential monotherapy and could be combined with IDEAYA’s DNA Damage Repair (DDR) therapies, such as the PARG inhibitor IDE161
The agreement involves an upfront fee, potential option exercise fee, development and regulatory milestone payments, and royalties, totaling up to $406.5 million
A development candidate for the B7H3/PTK7 topo-I-payload BsADC is anticipated to be nominated in the second half of 2024